수술 후 통증조절 목적으로 펜타닐과 병용되는 네포팜 vs. 케토롤락의 사용현황

김윤희¹ · 김영원² · 최경숙¹ · 이정화¹ · 이은숙¹ · 김승연² · 최영록^{3*} · 김은경^{2*}

¹분당서울대학교병원 약제부, ²서울대학교 약학대학, ³분당서울대학교병원 외과
(2018년 11월 27일 접수 · 2018년 12월 10일 수정 · 2018년 12월 11일 승인)

Concurrent Use of Nefopam vs. Ketorolac with Opioid Analgesic for Post-operative Pain Management

Yoon Hee Kim^{1¶}, Young Won Kim^{2¶}, Kyung Suk Choi^{1&}, Jung Hwa Lee^{1&}, Eunsook Lee^{1&}, Seungyeon Kim², YoungRok Choi^{3*}, and Euni Lee^{2*}

¹Department of Pharmacy, Seoul National University Bundang Hospital, Gyeonggi-do 13620, Republic of Korea

²College of Pharmacy & Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea

³General Surgery Center, Seoul National University Bundang Hospital, Gyeonggi-do 13620, Republic of Korea

(Received November 27, 2018 · Revised December 10, 2018 · Accepted December 11, 2018)

ABSTRACT

Objective: To compare the analgesic effects and adverse drug reactions (ADRs) of fentanyl intravenous patient-controlled analgesia (ivPCA) with nefopam, a centrally acting analgesic agent with demonstrated opioid sparing activity, as compared to ketorolac in a tertiary teaching hospital. **Methods:** A retrospective evaluation of electronic medical records was conducted on patient records including either nefopam or ketorolac with opioid ivPCA for post-operative pain management in general surgery department from January to December 2014. The status of pain control and ADRs were collected. **Results:** Out of 6,330 general surgery cases, nefopam was given in 153 prescriptions (6.9%) and ketorolac in 81 prescriptions (3.6%). The level of pain control was not different between two groups (70.9% vs. 75.3%; $p = 0.51$), but ADRs were more frequently reported in nefopam group (9.8% vs. 2.5%; $p < 0.05$). New ADRs of hot flushes ($n = 1$) and paresthesia in hands ($n = 1$) were reported in nefopam group and they were unlisted in the approved package insert. No serious ADRs were reported in both groups. **Conclusion:** Our findings presented that nefopam showed a similar analgesic effect and higher ADR rates compared to ketorolac as an adjuvant to fentanyl iv PCA for post-operative pain management in general surgery patients in South Korea.

KEY WORDS: Nefopam, ketorolac, postoperative pain management, analgesic effects, drug safety, adverse events, opioid analgesics

Optimal pain management represents a priority, as well as a clinical challenge, for healthcare professionals, since inadequate pain control following surgery may result in delayed patient recovery and subsequent discharge, as well as poor clinical outcomes.¹⁻⁴⁾ Although opioids have been reported as the main analgesics used in post-operative pain management³⁾ despite

their associated adverse drug reactions (ADRs), multimodal analgesia including the use of various analgesic agents such as non-steroidal anti-inflammatory drugs (NSAIDs) has been recommended.⁵⁾

Nefopam, a benzoxazocine analgesic and an analogue of diphenhydramine, was developed for the treatment of spasticity

[¶]These authors contributed equally to this work.

[&]These authors also contributed equally to this work.

*Correspondence to: Euni Lee, College of Pharmacy & Research Institute of Pharmaceutical Sciences, Seoul National University, 1, Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea
Tel: +82-2-740-8588, Fax: +82-2-880-9122
E-mail: eunilee@snu.ac.kr

*Co-corresponding Author: YoungRok Choi, General Surgery Center, Seoul National University Bundang Hospital, 82, Gumi-ro 173 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13620, Republic of Korea
E-mail: choiyoungrok@gmail.com

in the early 1970s.⁶⁾ As a centrally acting analgesic agent, nefopam exerts its action by inhibiting the reuptake of serotonin, noradrenaline, and dopamine⁶⁾. Although nefopam has demonstrated opioid-sparing effects when used in combination with opioid analgesics⁶⁻¹¹⁾ and a better safety profile in terms of renal function and platelet aggregation as compared with NSAIDs^{8,10)}, the approved package insert of nefopam (Acupan[®]) currently includes a warning of insufficient data supporting its concurrent use with opioid analgesics.¹²⁾

Nefopam is approved for use in acute pain, especially post-operative pain and lists the following adverse drug reactions (ADRs) in the approved package insert: gastrointestinal side effects, anorexia, nausea, vomiting, somnolence, dizziness, nervousness, sleep disturbance, insomnia, excitability, irritability, hallucinations, convulsions, headache, blurred vision, fatigue, hyperhidrosis, sweating, tachycardia, palpitations, thirst, pain at injection sites, etc.¹²⁾

The current study was designed to estimate the rate of concurrent use of nefopam with fentanyl intravenous patient-controlled analgesia (ivPCA) and to compare the analgesic effects and ADRs between nefopam vs. ketorolac with fentanyl ivPCA groups in post-operative patients using electronic medical records (EMRs) from a tertiary teaching hospital.

METHODS

Study design and study population

A retrospective evaluation of EMRs was carried out at a tertiary teaching hospital in South Korea which provides care for approximately 1.2 million outpatients and more than 60,000 inpatients annually. EMR of the hospital was supported by a proprietary healthcare information system which houses clinical data and built-in clinical decision tools to provide patient care services and hospital management. All hospitalized patient records in general surgery department from January to December 2014 were retrospectively identified and data on patient characteristics (age, body weight and height) and clinical characteristics (length of stay, type of surgery, duration of surgery, medications, the status of pain control, and associated ADRs) were collected by reviewing patient profiles, prescription records, and nursing charts available from EMRs.

This study was approved by the Seoul National University Bundang Hospital Institutional Review Board (IRB no. B-1508/312-117) and was granted a waiver of informed consent and documentation of consent for all patients.

Data on medications, ADR assessment, and pain control

Of two opioid medications delivered in ivPCA, i.e., fentanyl and oxycodone namely, the study focused on fentanyl as it is the most commonly prescribed in our clinical setting. As nefopam was first introduced in late 2013 the hospital, all prescription records for hospitalized patients were retrieved between January 1, 2014 and December 31, 2014 to describe a patterns of nefopam use as compared to ketorolac, i.e., the most frequently used analgesic agent with opioid ivPCA before the introduction of nefopam. We considered concurrent use of nefopam with fentanyl ivPCA (ivPCA-N) or ketorolac with fentanyl ivPCA (ivPCA-K) if these agents were prescribed on the same day, respectively.

Data on ADRs and causal inferences were retrieved from relevant 'ADR' sections in the EMRs, including documented patient-reported ADRs or symptoms recorded on nursing charts. ADR causality was assessed using tools such as the Naranjo Algorithm and the Korean Algorithm version 2.¹³⁻¹⁵⁾ A nefopam-related ADR was defined when causality assessment concluded an association with nefopam use was possible, probable, or certain, and the assessment was made by two independent pharmacists trained in causality assessment.

The study considered that pain was controlled if the nursing charts from EMRs included descriptions about reduced pain after nefopam or ketorolac administration and no subsequent prescriptions of analgesic agents were issued.

Statistical analysis

For estimating the rate of concurrent use of nefopam with fentanyl ivPCA and comparing the rates for nefopam vs. ketorolac use, descriptive statistics were used. Differences between ivPCA-N group and ivPCA-K group were evaluated using Chi-square test, Mann-Whitney *U*-test, or *t*-test. All analyses were performed using IBM SPSS Statistics version 21.0 (SPSS Inc, Chicago, IL, USA). A *p*-value <0.05 was considered as statistically significant.

RESULTS

Patterns of use of nefopam in post-operative pain management

A total of 6,330 general surgery cases in 2014 were identified, of which 2,315 (36.6%) cases involved the use of one or more injectable opioid analgesics as ivPCA. Of these 2,315 cases, fentanyl ivPCA was administered in 2,225 (35.2%) cases (Fig.

Fig. 1. The process of identifying the study population

Fig. 2. Prevalence of postoperative pain management with concurrent fentanyl ivPCA use at a tertiary hospital in Korea

1). Following initiation of fentanyl ivPCA, nefopam was given in 103 patient cases ($N=103$, 4.6%) with a total of 153 prescriptions (prescription per patient 6.9%) and ketorolac in 73 patient cases ($N=73$, 3.3%) with a total of 81 prescriptions (prescription per patient 3.6%) (Fig. 2).

There were no significant differences in patient characteristics between ivPCA-N group and ivPCA-K group as well as clinical characteristics in total operation time, fentanyl infusion rate or the prescribed fentanyl dosage (Table 1). There were no significant differences in the level of pain control (70.9% vs. 75.3%, $p=0.51$) (Table 1). However, the length of hospitalisation after surgery was significantly longer in ivPCA-N group, compared with ivPCA-K group (mean $\pm$ SD 14.5 days $\pm$ 13.0 vs 10.0 days $\pm$ 8.3, respectively; $p<0.05$) without significant differences in the operation time or the rate of laparoscopic surgery between the groups. The duration of concurrent analgesic use for ivPCA-N group was longer than ivPCA-K group (mean $\pm$ SD 1.5 days $\pm$ 1.2 vs 1.1 days $\pm$ 0.3, respectively; $p<0.05$).

Adverse drug reactions

Of 153 nefopam prescriptions in ivPCA-N group, ADRs occurred in 15 cases (9.8%) (Table 2), which included 12 documented ADRs (nausea $n=5$, dizziness $n=3$, tachycardia $n=2$, and sweating $n=2$) [15] and 3 ADRs that are not listed in the approved package inserts (vomiting $n=1$, hot flushes

Table 1. Characteristics of the study population with the concurrent fentanyl ivPCA use*

Characteristics	Nefopam (n = 103 cases)	Ketorolac (n = 73 cases)	p-value
Total number of prescriptions	153	81	-
Age, years	57.4 ± 14.6	53.0 ± 15.9	0.06 ^a
Body weight, kg	60.9 ± 15.9	60.6 ± 9.9	0.84 ^b
Height, cm	162.5 ± 8.5	161.6 ± 7.5	0.50 ^b
Length of hospitalization, day	14.5 ± 13.0	10.0 ± 8.3	<0.05
Total operation time, minute	246.9 ± 157.6	215.6 ± 114.2	0.31 ^a
Dosage of fentanyl ivPCA, microgram	1,355.8 ± 317.7	1,356.2 ± 321.0	0.89
Infusion rate of fentanyl ivPCA, mL/hr	1.0 ± 0.3	1.1 ± 0.5	0.40 ^b
Duration of the combined therapy, day	1.5 ± 1.2	1.1 ± 0.3	<0.05
Laparoscopic surgery, %	41.7	54.8	0.09 ^c
Pain control, %	70.9	75.3	0.51 ^c

Data presented as mean ± SD or %.

^aMann - Whitney U test.

^bStudent's t-test.

^cChi-square test.

ivPCA, intravenous patient-controlled analgesia.

Table 2. Adverse drug reactions with the concurrent fentanyl ivPCA use

	Nefopam (n = 153)	Ketorolac (n = 81)	p-value
Number (% prescriptions) of ADRs	15 (9.8)	2 (2.5)	<0.05 ^b
ADR descriptions, n (%)			
Nausea	5 (3.3)	1 (1.2)	
Dizziness	3 (2.0)	-	
Palpitation	2 (1.3)	-	
Sweating	2 (1.3)	-	
Vomiting	1 (0.7)	-	
Hot flushing ^a	1 (0.7)	-	
Paresthesia on hands ^a	1 (0.7)	-	
Bloody drainage	-	1 (1.2)	

^aADRs that are not described in the approved package insert.

^bChi - square test.

ADRs, adverse drug reactions; ivPCA, intravenous patient-controlled analgesia.

n = 1, and paresthesia in the hands n = 1). The overall prevalence of reported ADRs were significantly higher in ivPCA-N group than ivPCA-K group (9.8% vs. 2.5%; $p < 0.05$). (Table 2) Five out of 6 patients who had experienced gastrointestinal ADRs like nausea or vomiting were recipients of GI surgery. Nausea, vomiting, hot flushes and paresthesia subsided within 30 minutes of discontinuation of nefopam. No report of nefopam-related renal toxicity or serious ADRs were found.

Of 81 ketorolac prescriptions in ivPCA-K group, ADRs occurred in two cases (2.5%) (Table 2), which included: nausea (n = 1) and bloody drainage (n = 1), both of which are listed on the approved package insert.¹⁶⁾ There was no report of ketorolac-related renal toxicity or serious ADRs.

DISCUSSION

Latest practice guidelines on pain management have described the benefits of multimodal pain management combining analgesics with different mechanisms of action, thereby providing more effective pain relief, compared with single-modality pharmacotherapeutic interventions.⁵⁾ Although opioids are recognized for effective analgesia in the management of post-operative pain, their usefulness as monotherapy in post-operative pain control is hampered by their ADR profile, including nausea, vomiting, constipation, urinary retention, respiratory depression, drowsiness, dizziness, pruritus, bradycardia and hypotension.¹⁷⁾ NSAIDs are known to potentiate opioid analgesic effectiveness and decrease opioid-related adverse

effects in opioid-based PCA. Due to the safety related limitations of NSAIDs as PCA adjuvants related to their increased risk for GI ulceration and bleeding¹¹⁾, hypersensitivity reactions^{18,19)}, renal insufficiency in older patients⁶⁾, and cardiovascular risks²⁰⁾, the need for alternative adjuvant analgesics would appear reasonable and justifiable.

Our study showed nefopam was used as a PCA adjuvant in a South Korean tertiary teaching hospital, although it has not been approved for use for this particular indication. Nefopam, a benzoxazocine compound, is a non-opioid, non-steroidal, centrally acting analgesic that has been available in European countries since the mid-1970s.^{6,10)} Nefopam (Acupan[®]) exerts its analgesic effects by inhibiting the presynaptic reuptake of monoamine neurotransmitters involved in pain, including noradrenaline, serotonin and dopamine, and its antihyperalgesic effects by inhibiting post-synaptic *N*-Methyl-*D*-aspartate (NMDA) receptor activation.^{12,21)} Findings from our study also documented that nefopam was more prevalently prescribed soon after its availability in the Korean market as an adjuvant to fentanyl ivPCA for post-operative pain management than ketorolac. Although the level of pain control was not different between two groups, the rate of ADRs were more prevalent in nefopam group.

While studies documented that combination use of nefopam with morphine PCA demonstrated a morphine-sparing effect of approximately 35% without major side effects⁸⁾, we believe further studies are needed to document the efficacy and safety of nefopam as part of multimodal analgesia because the approved package insert of nefopam (Acupan[®]) described about insufficient data supporting its concurrent use with opioid analgesics.¹²⁾ Based on clinical judgment or evidence supported by published studies, doctors often prescribe drugs beyond their approved indications by the regulatory agencies. The practice of off-label prescribing is not infrequent as documented in various clinical settings and many countries.^{22,23)} Off-labeling prescriptions of nefopam or other various alternatives to NSAIDs may be considered in the management of post-operative pain in the form of multimodal analgesia as suggested in the literature.⁵⁾

Our study found ‘unlisted’ ADRs related to nefopam use as an opioid PCA adjuvant in post-operative pain management, such as body heat sensation and paresthesia of hand. Pyrexia of non-infective etiology within the first 48 hours post-surgery have been previously reported in general surgery patients^{24,25)}, with normal inflammatory host response to surgery²⁶⁾ or other benign causes cited as the most common causes.²⁷⁾ Although

neuropathies following surgery due to damage to soft and nerve tissues have been described in anaesthetized or sedated patients²⁸⁾, similar types of ADRs were not found in ivPCA-K group and, therefore, further evaluations of spontaneous reportings or large-scale epidemiological studies are needed to clarify the causal association between nefopam and paresthesia.

Several limitations should be considered in the interpretation of our study findings. This was a retrospective study; hence the efficacy evaluation of analgesics in pain control could lack sufficient details. In addition, there is a potential for random errors because of small sample size. Therefore, further studies with a large scale are needed. As similar to studies using secondary data, only accessible information from the EMRs were used for safety assessment using the Naranjo Algorithm. Continuous use of ketorolac beyond 2 days post-surgery was usually restricted and the drug costs would not be covered by the health insurance. Therefore, the differences of duration of the combined therapy could partially explain the rate of ADRs between two groups. However, we believe that the mean differences of the therapy duration between two groups being 0.4 days could not sufficiently explain the rate differences of ADRs.

In conclusion, this is a first retrospective study which directly evaluated the efficacy and safety of concurrent use of nefopam compared to ketorolac with opioid at clinical setting in South Korea. Our study showed that nefopam was more commonly used than ketorolac as an adjuvant to fentanyl ivPCA for post-operative pain management with similar efficacy in pain control and higher ADR rates were observed in nefopam group at a tertiary teaching hospital in South Korea. We reported three new ADRs not listed in the approved package insert of nefopam. As ketorolac can be used only limited days in South Korea healthcare system, nefopam might be suggested as an alternative analgesic concurrently used with fentanyl. Continuous efforts are needed in monitoring of efficacy and safety outcomes while using nefopam concurrently with opioid analgesic agent.

ACKNOWLEDGMENT

The study was supported in part by Creative-Pioneering Researchers Program through Seoul National University.

DECLARATION OF CONFLICTING INTERESTS

All authors declare that there is no conflict of interest.

REFERENCES

- Sharrock NE, Cazan MG, Hargett MJ, *et al.* Changes in mortality after total hip and knee arthroplasty over a ten-year period. *Anesth Analg* 1995; 80(2): 242-8.
- Katz J, Jackson M, Kavanagh BP, *et al.* Acute pain after thoracic surgery predicts long-term post-thoracotomy pain. *Clin J Pain* 1996; 12(1): 50-5.
- Rawal N. Current issues in postoperative pain management. *Eur J Anaesthesiol* 2016; 33(3): 160-71.
- Gan TJ, Habib AS, Miller T, *et al.* Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey. *Curr Med Res Opin* 2014; 30(1): 149-60.
- Chou R, Gordon DB, de Leon-Casasola OA, *et al.* Guidelines on the management of postoperative pain. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. *J Pain* 2016; 17(2): 131-57.
- Evans MS, Lysakowski C and Tramèr MR. Nefopam for the prevention of postoperative pain: quantitative systematic review. *Br J Anaesth* 2008; 101(5): 610-7.
- Kapfer B, Alfonsi P, Guignard B, *et al.* Nefopam and ketamine comparably enhance postoperative analgesia. *Anesth Analg* 2005; 100(1): 169-74.
- Du Manoir B, Aubrun F, Langlois M, *et al.* Randomized prospective study of the analgesic effect of nefopam after orthopaedic surgery. *Br J Anaesth* 2003; 91(6): 836v41.
- Mimoz O, Incagnoli P, Josse C, *et al.* Analgesic efficacy and safety of nefopam vs. propacetamol following hepatic resection. *Anaesthesia* 2001; 56(6): 520-5.
- Hwang BY, Kwon JY, Lee DW, *et al.* A Randomized Clinical Trial of Nefopam versus Ketorolac Combined With Oxycodone in Patient-Controlled Analgesia after Gynecologic Surgery. *Int J Med Sci* 2015; 12(8): 644-9.
- Dordoni PL, Della Ventura M, Stefanelli A, *et al.* Effect of ketorolac, ketoprofen and nefopam on platelet function. *Anaesthesia* 1994; 49(12): 1046-9.
- Pharmbio Korea co., Ltd. AcupanTM (package insert). South Korea: Pharmbio Korea co., Ltd, 2008.
- Naranjo CA, Busto U, Sellers EM, *et al.* A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther* 1981; 30(2): 239-45.
- Hong KS, Park BJ, Sin SG, *et al.* Development of a Korean algorithm for causality assessment of adverse drug reactions. *Korean J Clin Pharmacol Ther* 2002; 10: 129-42.
- Danan G and Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. *J Clin Epidemiol* 1993; 46(11): 1323-30.
- Daewoo Pharm co., Ltd. KetolacTM (package insert). South Korea: Daewoo Pharm co., Ltd, 2001.
- William JD. Drug information handbook Drug Information Handbook. 22nd ed. Hudson, Ohio, Lexi-Comp Inc, 2013; p762-4.
- Murray MD and Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. *Annu Rev Pharmacol Toxicol* 1993; 33: 435-65.
- Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. *Anaesth Intensive Care* 2005; 33(3): 311-22.
- Vacha ME, Huang W and Mando-Vandrick J. The role of subcutaneous ketorolac for pain management. *Hosp Pharm* 2015; 50(2): 108-12.
- Novelli A, Diaz-Trelles R, Groppetti A, *et al.* Nefopam inhibits calcium influx, cGMP formation, and NMDA receptor-dependent neurotoxicity following activation of voltage sensitive calcium channels. *Amino Acids* 2005; 28(2): 183-91.
- Shah SS, Hall M, Goodman DM, *et al.* Off-label drug use in hospitalized children. *Arch Pediatr Adolesc Med* 2007; 161(3): 282-90.
- Lee E, Teschemaker AR, Johann-Liang R, *et al.* Off-label prescribing patterns of antidepressants in children and adolescents. *Pharmacoepidemiol Drug Saf* 2012; 21(2): 137-44.
- Garibaldi RA, Brodine S, Matsumiya S, *et al.* Evidence for the non-infectious etiology of early postoperative fever. *Infect Control* 1985; 6(7): 273-7.
- Galicier C and Richet H. A prospective study of postoperative fever in a general surgery department. *Infect Control* 1985; 69(12): 487-90.
- Saavedra F, Myburg C, Lanfranconi MB, *et al.* Postoperative fever in orthopedic and urologic surgery. *Medicina (B Aires)* 2008; 68(1): 6-12.
- Lesperance R, Lehman R, Lesperance K, *et al.* Early postoperative fever and the "routine" fever work-up: results of a prospective study. *J Surg Res* 2011; 171(1): 245-50.
- Johnson RL, Warner ME, Staff NP, *et al.* Neuropathies after surgery: Anatomical considerations of pathologic mechanisms. *Clin Anat* 2015; 28(5): 678-82.